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Osteogenesis imperfecta (OI), also known as brittle bone disease, is a clinically and genetically hetero-
geneous disorder primarily characterized by susceptibility to fracture. Although OI generally results from
mutations in the type I collagen genes, COL1A1 and COL1A2, the relationship between genotype and pheno-
type is not yet well understood. To provide additional data for genotype–phenotype analyses and to deter-
mine the proportion of mutations in the type I collagen genes among subjects with lethal forms of OI, we
sequenced the coding and exon-ﬂanking regions of COL1A1 and COL1A2 in a cohort of 63 subjects with
OI type II, the perinatal lethal form of the disease. We identiﬁed 61 distinct heterozygous mutations in type
I collagen, including ﬁve non-synonymous rare variants of unknown signiﬁcance, of which 43 had not
been seen previously. In addition, we found 60 SNPs in COL1A1, of which 17 were not reported previously,
and 82 in COL1A2, of which 18 are novel. In three samples without collagen mutations, we found inactivating
mutations in CRTAP and LEPRE1, suggesting a frequency of these recessive mutations of 5% in OI type II.
A computational model that predicts the outcome of substitutions for glycine within the triple helical domain
of collagen a1(I) chains predicted lethality with 90% accuracy. The results contribute to the understanding
of the etiology of OI by providing data to evaluate and reﬁne current models relating genotype to phenotype
and by providing an unbiased indication of the relative frequency of mutations in OI-associated genes.
INTRODUCTION
Osteogenesis imperfecta (OI), also known as brittle bone
disease, is a heterogeneous disorder characterized by suscepti-
bility to fracture. The disease varies in severity from mild (OI
type I) to perinatal lethal (OI type II) and exhibits both auto-
somal dominant and recessive inheritance patterns. The dom-
inantly inherited forms that account for 90% of infants and
adults with OI result from heterozygous mutations in COL1A1
or COL1A2, the genes that encode the proal(I) and proa2(I)
chains of type I collagen, the major structural protein of
bone. Recessively inherited OI results in many cases from
homozygous or compound heterozygous mutations in
CRTAP and LEPRE1 (1–3), which encode cartilage-associ-
ated protein and leucine proline-enriched proteoglycan (lepre-
can; prolyl-3-hydroxylase-1), respectively. These two proteins
are part of a complex that hydroxylates a single proline residue
at position 986 of the triple helical domain of the proa1(I)
chain of collagen during its biosynthesis. Mutations in each
of the four genes, COL1A1, COL1A2, CRTAP and LEPRE1,
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Advance Access published on November 7, 2008lead to the production of type I collagen molecules that
undergo excessive post-translational modiﬁcation, at least in
cultured dermal ﬁbroblasts (1,2,4).
The relationship between the clinical severity of OI and the
causative mutations is only partially understood, despite the
availability of mutation sequences from .800 individuals
with OI (5). The mildest forms of OI generally result from het-
erozygous mutations that lead to the loss of mRNA from one
COL1A1 allele due to the presence of premature termination
codons in the coding sequence of that allele (6–8). Different
classes of mutations (single codon nonsense mutations, frame-
shift mutations and splice site mutations that result in use of
out-of-frame cryptic splice sites) can all lead to activation of
the nonsense-mediated mRNA decay pathway (6). In the
more severe forms of OI in which there is often bone deform-
ity, increased fracture rate, dentinogenesis imperfecta and
short stature, the most frequent mutations result in substitution
of the glycine residue in almost any of the 338 Gly-X-Y tri-
peptide motifs found in the triple helical region of each of
the proa chains. For these mutations, it appears that the
chain in which the mutation occurs, the position of the substi-
tuted glycine and the substituting residue all contribute to phe-
notypic outcome (9). Yet the nature of these relationships is
not yet evident. This may reﬂect the possibility that different
mutations result in lethality by distinct pathways (10–12).
Given the diversity of mechanisms underlying the lethal
forms of OI, understanding the relationship between genotype
and phenotype requires mutation detection and clinical data
from a larger number of individuals with OI type II than
currently available. To initiate this process, we identiﬁed the
disease-associated mutations in 62 subjects with OI type II.
In 59 cases we found heterozygous mutations in the type I
collagen genes, of which 23 of the distinct causative mutations
in COL1A1 and 15 in COL1A2 are novel. In three samples
without collagen mutations, we found homozygous inactivating
mutations in CRTAP (one) and LEPRE1 (two individuals homo-
zygous for the same West African allele). Since the subjects
were selected based only on phenotype and the production of
abnormal type I procollagen molecules, this provides an
unbiased indication of the frequency of mutations in these
genes in OI type II. The novel collagen mutations provide a
valuable addition to the set of known mutations available for
studying genotype–phenotype relationships.
RESULTS
COL1A1 and COL1A2 SNPs
A total of 203 distinct genomic sequence variations were
identiﬁed in the type I collagen genes among the 63 subjects
with OI type II, 98 in COL1A1 and 105 in COL1A2
(Table 1). This includes 142 SNPs (Supplementary Material,
Tables S1 and S2) and 61 mutations and non-synonymous
sequence variants of unknown signiﬁcance (Table 2). Of the
142 SNPs, 35 are novel: 17 in COL1A1 and 18 in COL1A2.
Of the 76 common SNPs with minor allele frequency
(MAF) .0.05 listed in dbSNP which are located within the
genomic regions of the resequencing effort (25 in COL1A1
and 51 in COL1A2), all but three (rs41317349 and
rs2586494 in COL1A1 and rs17073 in COL1A2) are seen in
our sample set. The SNPs rs41317349 and rs2586494 are par-
ticularly common in the African-American and Asian popu-
lations, respectively (13), so their absence may reﬂect the
ethnicities in our OI patient cohort that is largely Caucasian.
Approximately 90% of the identiﬁed SNPs in each gene are
intronic (53 of 60 in COL1A1 and 73 of 82 in COL1A2),
and only one non-synonymous SNP was recognized in each
gene, rs1800215 (p.Ala1075Thr) in COL1A1 and rs42524
(p.Ala549Pro) in COL1A2. The rs42524 SNP is present at fre-
quencies of 17.7, 26.0, 9.38 and 30.2% in African-American,
Hispanic, Chinese and Caucasian populations of healthy indi-
viduals, respectively (13). In the same study, rs1800215 was
found at a frequency of 6.25% in African-American popu-
lation (negligible in other ethnic groups).
Three intronic SNPs in COL1A2 with MAF 0.05 or
greater among the OI individuals were not seen previously
in our healthy cohort (13) (Table 3). One, with an MAF of
4.1%, is a novel SNP, whereas the other two were reported
previously. rs34026686 has only one submitter listed in
dbSNP and no allele frequency information, suggesting that
it could be a rare allele. However, in our OI sample set it
has an MAF of 14.4%. rs10228528 has an MAF of 4.8%
among the OI subjects and is listed with an MAF of only
0.8% among the Caucasians (CEU), although it is known to
be more common in Han Chinese (CHB) and Yoruba
African (YRI) populations (14).
COL1A1 and COL1A2 mutations
We identiﬁed mutations in type I collagen genes in 59 of the
63 samples (Table 2). In one sample (C2) in which protein
studies indicated a rearrangement in COL1A1, no mutation
was detected in genomic DNA but cDNA analysis revealed
a nine-exon deletion (exons 40–48). Of the 59 samples in
which collagen mutations were identiﬁed, 37 had mutations
in COL1A1 and 22 in COL1A2. Among the 34 distinct
COL1A1 causative mutations, 26 resulted in substitution for
a glycine within the Gly-X-Y triplet domain of the triple
helix, four altered splice sites and resulted in exon skipping,
one resulted in exon skipping from a deletion spanning
coding and intronic sequence, one was a nine-exon deletion
from genomic DNA, one was a duplication of nine nucleotides
and the last (p.Asp1413Asn) altered a single residue in the
carboxyl-terminal propeptide. Our unpublished studies
suggest that this last mutation interferes with chain associ-
Table 1. Distribution of distinct genomic sequence variations in type I col-
lagen genes
COL1A1 COL1A2
Previously
reported
Novel Previously
reported
Novel
Mutations Coding
a 11 21 7 12
Splicing 0 6 0 4
SNPs Synonymous 4 2 5 3
Non-synonymous 1 0 1 0
Intronic 38 15 58 15
aIncludes causative mutations and sequence variants of unknown
signiﬁcance.
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Subject COL1A1 COL1A2 References
a
cDNA Protein Triple
helix
Exon cDNA Protein Triple
helix
Exon
Missense mutations
F1 c.1058G.A p.Gly353Asp 175 17
E6 c.1103G.T p.Gly368Val 190 17
E1 c.1273G.A p.Gly425Ser 247 19 (5,28)
b
H2 c.1364G.A p.Gly455Asp 277 21 c.700C.T p.Arg234Cys 144 15
F5 c.1409G.T p.Gly470Val 292 21
D8 c.1526G.T p.Gly509Val 331 23
G4 c.1643G.C p.Gly548Ala 370 24
A1 c.1804G.A p.Gly602Arg 424 26 (29)
G1 c.1804G.A p.Gly602Arg 424 26 (29)
D7 c.1814G.A p.Gly605Asp 427 26
G7 c.1840G.C p.Gly614Arg 436 27
A7 c.2218G.C p.Gly740Arg 562 32
c.1168G.A p.Ala390Thr 212 18
E4 c.2425G.A p.Gly809Ser 631 36 (5,30)
E8 c.2470G.C p.Gly824Arg 646 37
H4 c.2533G.C p.Gly845Arg 667 37 (5,31)
H5 c.2542G.C p.Gly848Arg 670 37
B1 c.2596G.A p.Gly866Ser 688 38 (5,32,33)
b
B7 c.2623G.A p.Gly875Ser 697 39 (5)
c.863A.T p.Glu288Ala 110 13
E5 c.2650G.A p.Gly884Ser 706 39
G2 c.2650G.A p.Gly884Ser 706 39
E3 c.2687G.A p.Gly896Asp 718 40
C5 c.2839G.T p.Gly947Cys 769 41 (5)
c.2563A.C p.Asn855His 677 38
G3 c.2930G.A p.Gly977Asp 799 41
B3 c.3001G.T p.Gly1001Cys 823 42
B2 c.3065G.T p.Gly1022Val 844 43 (5,34)
F3 c.3065G.T p.Gly1022Val 844 43 (5,34)
B5 c.3164G.A p.Gly1055Asp 877 44
G8 c.3280G.A p.Gly1094Ser 916 46
C6 c.3299G.A p.Gly1100Asp 922 46 (5)
c.436C.A p.Pro146Thr na 5
D6 c.4237G.A p.Asp1413Asn na 51 (17)
F2 c.847G.C p.Gly283Arg 193 17
F8 c.1190G.A p.Gly397Glu 307 21
D4 c.1360G.T p.Gly454Cys 364 24 (5)
A3 c.1369_1370GG.CT p.Gly457Leu 367 24
F7 c.1577G.A p.Gly526Glu 436 27 (5,35)
c
E7 c.1685G.T p.Gly562Val 472 29
A6 c.2215G.C p.Gly739Arg 649 37 (5)
c
F6 c.2243G.T p.Gly748Val 658 37
H3 c.2369G.A p.Gly790Asp 700 39 (36)
B8 c.2567G.T p.Gly856Val 766 41
E2 c.2845G.A p.Gly949Ser 859 44 (5,37,38)
b
H7 c.2864G.A p.Gly955Asp 865 44
A4 c.3080G.A p.Gly1027Glu 937 46 (5)
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Subject COL1A1 COL1A2 References
a
cDNA Protein Triple
helix
Exon cDNA Protein Triple
helix
Exon
H6 c.3148_3156dupGCTCCTGGT p.1050_1052dupAlaProGly 874 44
C7 c.1380_1397delCCCC p.461_466delProAlaG 371_376 24
GCTGGAAAAGAAGG lyLysGluGly
G5 c.2113_2121del p.705_707delAlaGlyPro 615_617 35 (16)
GCTGGTCCT
F4 c.2391_2393dupCCC p.Pro798dup 708 39
C8 c.2415_2432delCCCT p.806_811delProProG
CCTGGTCCCCCTGG lyProProGly 716_721 40
H1 c.3171_3188delTCCT p.1058_1062delProSe
TCTGGCCCTGCTGG rGlyProAlaGly 968_972 48
Splicing
C4 c.957þ5G.A IVS14þ5G.A Skip exon 14
A5 c.2509_2559þ9del Skip exon 37
B6 c.3261þ1G.A IVS45þ1G.A Skip exon 45
H8 c.3423þ2T.A IVS47þ2T.A Skip exon 47
A2 c.3424-1G.C IVS47-1G.C Skip exon 48
C2 Genomic
deletion of
exons 40–48
B4 c.1701_1719þ6del Skip exon 29
G6 c.1720-2A.G IVS29-2A.G Unknown–?skip
exon 30
C1 c.2673þ1G.A IVS41þ1G.A Skip exon 41
A8 Not resolved Moderate level
of skip exon
46
aReferences are listed for previously reported mutations; this ﬁeld is left blank for novel mutations.
bReported in both lethal and non-lethal OI cases.
cReported as OI type III.
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3ation. Among the 22 causative mutations we identiﬁed in
COL1A2, 13 resulted in substitution for triple helix glycine
residues, three were deletions of different 18 bp fragments,
two were splice site mutations that resulted in exon skipping,
one was a 3 bp duplication and one a 9 bp deletion. Two
additional mutations resulted in exon skipping: one deletion
spanning coding and intronic sequence and the other one not
yet resolved. In sample H2, we identiﬁed a mutation in
COL1A1 that is most likely responsible for the OI type II
phenotype c.1364G.A, p.Gly455Asp, Gly277Asp in the
triple helix and, in addition, a second mutation, c.700C.T,
p.Arg234Cys, Arg144Cys in the triple helical domain of
COL1A2. Substitutions of arginine by cysteine in the triple
helical domain of proa1(I) chains has been associated with
classical forms of Ehlers–Danlos syndrome (15). We have
not been able to study parental samples to determine if
there is a phenotype associated with the COL1A2 sequence
alteration. The 38 novel, causative mutations represent a
24% addition to the set of 159 distinct mutations in COL1A1
and COL1A2 associated with lethal forms of OI published
by the OI consortium (99 and 44 unique substitutions
for glycine in al(I) and a2(I), respectively, and seven and
nine unique splicing mutations in COL1A1 and COL1A2,
respectively) (5).
As seen previously, the most common mutations are mis-
sense mutations that result in substitution for triple helical
glycine residues and represent 80 and 60% of the observed
mutations in COL1A1 and COL1A2, respectively, in this set.
Twice as many were observed in COL1A1 as in COL1A2
(26 versus 13), consistent with the set of mutations reported
by the OI consortium, in which 67% of the lethal glycine mis-
sense mutations occurred in COL1A1 (5). We also identiﬁed
mutations affecting splice sites, insertions and deletions in
the triple helical region of multiples of three amino acids
and mutations in repetitive regions, all of which have been
discussed previously regarding OI (5,16). Sixteen of the 18
mutations previously seen were reported in at least one case
of lethal OI. Although c.3423þ2T.A (IVS47þ2T.A) in
COL1A1 has not been described previously, mutation of
the adjacent G of the obligate GT at the donor site
(c.3423þ1G.A, IVS47þ1G.A) was found in one patient
with lethal OI (5).
The data set also includes some unique features. The
COL1A2 mutation c.1369_1370GG.CT, p.Gly457Leu is the
ﬁrst observed leucine for glycine substitution in a type I col-
lagen gene and the only known example of a dinucleotide
mutation in a glycine codon in this gene. The c.700C.T,
p.Arg234Cys mutation is the ﬁrst mutation in which arginine
is replaced by cysteine in the triple helical domain of
proa2(I). Four additional individuals with substitutions for
glycine in proa1(I) chains also had a second amino substi-
tution that affected a non-glycine residue in proa1(I) chains,
three in the triple helical region (p.Glu288Ala, Glu110Ala in
the triple helix, p.Ala390Thr, Ala212Thr in the triple helix
and p.Asn855His, Asn677His in the triple helix) and one in
the N-terminal propeptide (p.Pro146Thr). None of these vari-
ations have been reported previously although the
p.Ala390Thr was seen in one other individual in the diagnostic
setting (unpublished data). The contribution of the non-glycine
substitution to the phenotype is not known; however,
p.Glu288Lys (c.862G.A) was observed in a patient with OI
type I who also had a p.Asp1219Glu in the C-propeptide clea-
vage site, as well as in the patient’s unaffected parent (17),
suggesting that substitution of the glutamic acid, at least
with lysine, does not cause lethal disease. It is not known
whether the pairs of mutations are co-allelic.
Phenotype prediction for glycine substitutions in proa1(I)
We are developing a computational method for predicting OI
phenotype of collagen mutations.
The mutations reported here provide an important opportu-
nity to evaluate the current implementation of the model,
which was trained on the OI consortium mutations (5), on
new data. Of the 29 patients with mutations resulting in substi-
tution of a triple helical glycine in proa1(I) chains, the clinical
outcome in 26 (90%) is predicted correctly (Table 4). Of the
17 unique, novel mutations not included in the training set,
15 (88%) were classiﬁed correctly. The model can also be
applied to serine and cysteine substitutions for glycine in the
triple helical region of proa2(I) but no novel mutations of
this type were identiﬁed. The three COL1A1 mutations with
incorrect predictions are (i) p.Gly353Asp, Gly175Asp in the
triple helix, which lies one glycine N-terminal to the
model’s cutoff between lethal and non-lethal, (ii) a rare
lethal alanine substitution and (iii) p.Gly866Ser, Gly688Ser
in the triple helix, which is non-lethal in ﬁve of six previously
observed cases.
LEPRE1 and CRTAP mutations
We found no mutations in type I collagen genes in four
samples and in three of those we identiﬁed mutations in
genes in which mutations were recently recognized to give
rise to recessive forms of severe/lethal OI. In two of those
samples, D1 and D3, there is homozygosity for a recently
recognized splice site mutation in the LEPRE1 gene
(c.1080þ1G.T, IVS5þ1G.T) that is of West African
origin and is a cause of lethal OI in the African-American
community in the USA (1). The ethnic origin of the two
families was not stated. In a third infant, C3, there was
homozygosity for a splice site mutation in the CRTAP gene
(c.471þ2C.A, IVS1þ2C.A). No consanguinity was
reported in the parents.
Based on the small number of patients in our set with
mutations in the LEPRE1 and CRTAP genes, an estimate of
the proportion of OI type II patients with recessive mutations
in these two genes is 4.8% (90% conﬁdence interval
Table 3. Common SNPs in COL1A2
Genomic
position
refSNP
cluster
ID
a
Major
allele
Minor
allele
MAF in
OI
subjects
MAF in
CEU
a
MAF in
CHB
a
MAF in
YRI
a
93863673 Novel A G 0.041 No data No data No data
93878223 rs34026686 G A 0.144 No data No data No data
93883010 rs10228528 G A 0.048 0.008 0.31 0.25
aAccording to dbSNP build 129.
Human Molecular Genetics, 2009, Vol. 18, No. 3 4671.5–12.4%). This extends an earlier estimate that CRTAP
mutations cause 2–3% of cases of lethal OI (2). Because
of the measured frequency of LEPRE1 heterozygosity in the
African-Americans in the USA (18,19), these mutations may
account for a signiﬁcant proportion of the severe forms of
OI in the USA among that group.
DISCUSSION
We have identiﬁed mutations in samples from 62 subjects with
OI type II in whose DNA we sequenced the complete coding
regions and ﬂanking intronic regions of the two type I collagen
genes, COL1A1 and COL1A2. In these samples, 37 had causa-
tive mutations in COL1A1 and 22 in COL1A2, of which 38
distinct mutations had not been reported previously, a 24%
addition to the published set of unique missense and splicing
mutations in these two genes associated with a lethal pheno-
type (5). Among the four individuals in whom we did not
identify mutations in type I collagen, we found one who was
homozygous for a CRTAP inactivating mutation and two
who were homozygous for a known LEPRE1 mutation
common in the African-American population derived from
West Africa. One sample remains incompletely characterized
but these cells make abnormal type I collagen molecules.
Since the samples were selected by two criteria, a clinical
picture consistent with a lethal OI phenotype (although some
were identiﬁed by ultrasound in the second trimester) and
cells that made overmodiﬁed type I collagens, these results
provide an estimate of the relative frequencies of the spectrum
of mutations associated with lethal OI.
The data suggest that there are multiple pathways that lead
to lethality. We identiﬁed mutations in OI type II subjects
likely to cause impaired post-translational modiﬁcation of pro-
collagen either because of (i) altered sequences in the triple
helical domain of the proa chains of type I collagen, (ii)
impaired chain association as a result of mutations in the
carboxyl-terminal propeptide or (iii) alterations in helix propa-
gation that result from failure to bring the prolyl cis–trans iso-
merase to the molecule (e.g. CRTAP and LEPRE1 mutations)
(1–3,18,20). Mutations that alter the sequences of the triple
helical domains of the chains of type I procollagen can
affect the thermal stability of the molecules (12,21), interfere
with secretion efﬁciency (22), disrupt the chain register (23) or
interfere with ligand binding or other interaction sites (5,24).
Models relating genotype to phenotype must capture the
diversity of these mechanisms. We allow for this complexity
by using a composite predictive model (12). The high accu-
racy in predicting the lethality of the newly sequenced
mutations is consistent with the hypothesis that substitutions
of glycine by serine and mutations that substitute bulky
amino acids for glycine carboxy-terminal to residue 178 in
the triple helical region of proa1(I) differ in the manner or
extent to which they disrupt collagen structure or function.
Triple helix position 178 was modeled as the end of the predo-
minantly non-lethal N-terminal region based on available data.
The newly identiﬁed lethal mutation Gly175Asp suggests that
position 175 may be a better cutoff. Because the current data
set is limited to OI type II mutations, a more complete evalu-
ation of the model requires non-lethal cases. Additional
mutations are needed to reﬁne other imprecise aspects of the
model including whether the cutoff position depends on the
residue replacing glycine and the determinant of lethality of
substitutions of glycine by cysteine in the proa1(I) chains.
The use of the composite model framework will allow
incorporation of other features that may contribute to lethality,
such as individual variation and sites of functional importance,
when sufﬁcient data are available.
Exceptions to this model may have implications for our
understanding of collagen biology. For example, the model
misclassiﬁes Gly370Ala in the triple helix of proa1(I) as
non-lethal. This suggests that a region around residue 370
may have important function and that its disruption can be
lethal. Indeed, substitution of the glycine at 376 by alanine
is lethal (5). This region overlaps a binding site for a small
proteoglycan (decorin) on collagen molecules (25,26), but it
seems unlikely that disturbance of binding of decorin, by
itself, is lethal as a decorin knockout mouse does not have
OI, despite dramatic alterations in ﬁbrillogenesis (27).
It was proposed recently that some regions of the triple
helical domain of type I collagen molecules may lack
mutations or have exclusively lethal mutations because disrup-
tion interferes with a critical function (although these func-
tions have not been clearly identiﬁed) (5). Four of the novel
mutations in COL1A1, which result in the substitutions
Gly706Ser, Gly718Asp, Gly799Asp and Gly916Ser in the
triple helical domain, lie within ‘lethal-only’ regions that
overlap the proposed major ligand binding regions MLBR2
Table 4. Prediction of lethality for COL1A1 glycine missense mutations
Subject Mutation Triple
helix
position
Lethality in
training set
a
Prediction Correct?
F1 p.Gly353Asp 175 na Non-lethal No
E6 p.Gly368Val 190 na Lethal Yes
E1 p.Gly425Ser 247 Lethal Lethal Yes
H2 p.Gly455Asp 277 na Lethal Yes
F5 p.Gly470Val 292 na Lethal Yes
D8 p.Gly509Val 331 na Lethal Yes
G4 p.Gly548Ala 370 na Non-lethal No
A1 p.Gly602Arg 424 na Lethal Yes
G1 p.Gly602Arg 424 na Lethal Yes
D7 p.Gly605Asp 427 na Lethal Yes
G7 p.Gly614Arg 436 na Lethal Yes
A7 p.Gly740Arg 562 na Lethal Yes
E4 p.Gly809Ser 631 Lethal Lethal Yes
E8 p.Gly824Arg 646 na Lethal Yes
H4 p.Gly845Arg 667 Lethal Lethal Yes
H5 p.Gly848Arg 670 na Lethal Yes
B1 p.Gly866Ser 688 Non-lethal Non-lethal No
B7 p.Gly875Ser 697 Lethal Lethal Yes
E5 p.Gly884Ser 706 na Lethal Yes
G2 p.Gly884Ser 706 na Lethal Yes
E3 p.Gly896Asp 718 na Lethal Yes
C5 p.Gly947Cys 769 Lethal Lethal Yes
G3 p.Gly977Asp 799 na Lethal Yes
B3 p.Gly1001Cys 823 Lethal Lethal Yes
B2 p.Gly1022Val 844 Lethal Lethal Yes
F3 p.Gly1022Val 844 Lethal Lethal Yes
B5 p.Gly1055Asp 877 na Lethal Yes
G8 p.Gly1094Ser 916 na Lethal Yes
C6 p.Gly1100Asp 922 Lethal Lethal Yes
ana, not applicable.
468 Human Molecular Genetics, 2009, Vol. 18, No. 3and MLBR3 (5,26). Interestingly, Gly688Ser, present in both
lethal and non-lethal cases, lies near the edge of MLBR2. In
COL1A2, three novel mutations were identiﬁed, which fall
into lethal-only regions 2 (Gly472Val), 6 (Gly766Val) and 7
(Gly865Asp). In contrast, mutations in COL1A1 that alter resi-
dues in triple helix regions 328–346 and 418–436, proposed
to be of critical importance due to a lack of observed
mutations (5), contain four mutations in our data set
(Gly331Val, Gly424Arg, Gly427Arg and Gly436Arg),
suggesting that the previous absence of mutations was due
to sampling. It is clear that to this point sampling of the
almost 2000 possible substitutions of triple helical glycines
by other residues in each chain is sufﬁciently incomplete
that it is difﬁcult to draw broad conclusions about the function
of particular regions of the triple helical domain based on the
absence of mutations.
Of the substitutions for glycine in the triple helical domain
encoded by COL1A1 identiﬁed here, 16 of the 26 distinct
mutations are novel. According to published models (5,9,12),
almost all substitutions of glycine by valine, aspartic acid, glu-
tamic acid, arginine and tryptophan between residues 178 and
1012 of the triple helix in proa1(I) chains should be lethal.
Using codon substitution tables, this suggests that a minimum
of 900 of the possible non-synonymous mutations in this
region will have a lethal effect. Only 100 distinct lethal
glycine substitutions in this region were reported previously,
including 49 replacements by alanine, serine and cysteine (5).
With the relatively low coverage of these mutations to date,
most newly studied infants with lethal OI will have previously
unrecognized mutations. Mutations in COL1A2 are less likely to
be lethal, and it has been more difﬁcult to locate the domains in
which they occur. Of the mutations identiﬁed here, 13 of the
COL1A2 mutations resulted in substitutions for glycine. Of
these, six have been previously encountered in infants with
lethal OI but the remaining seven were seen for the ﬁrst time
and six of them fell in domains of the triple helix not previously
thought to carry lethal mutations. This suggests that there are
still too few lethal mutations, or mutations overall, in the
COL1A2 gene to accurately predict the outcome on the basis
of any proposed model.
Nearly 10% of the subjects in this study (ﬁve of 59) with a
type I collagen mutation have a second missense alteration,
including one individual with a mutation in both COL1A1
and COL1A2. Although the glycine substitution itself is prob-
ably sufﬁcient for lethality in these cases, the additional vari-
ations may inﬂuence the phenotype resulting from less
disruptive mutations. Complete sequencing of both genes
and reporting of all sequence variations found will be import-
ant for assessing the role of multiple mutations in the develop-
ment of disease.
These studies indicate that recurrence in families in which a
child with lethal OI is born is increased as a result of parental
carrier status for recessive mutations in addition to the well-
known risk of parental mosaicism for dominant mutations.
For mutations in the COL1A1 gene, it is clear that substitution
of glycine residues by large amino acids carboxyl-terminal to
position 178 in the triple helical domain of the proa1(I) chains
carries a high risk of lethal outcome, something that can be
transferred to clinical utility. It is clear that many effects of
mutations on behavior of collagen molecules need to be
taken into account when determining how they result in
lethal mutations. Even in the absence of well-deﬁned path-
ways and mechanisms, the accumulation of mutations with
associated clinical data is an important part of providing the
basis for rational counseling of families and represents the
ﬁrst step in forming a truly informative model for how
mutations result in phenotypes.
MATERIALS AND METHODS
Subject population
We selected 64 DNA samples from unrelated individuals from
the Connective Tissue Biopsy Program Repository, an IRB
approved activity at the University of Washington that
allows further analysis of stored samples. The referral diagno-
sis for all selected samples was a lethal form of OI. For all
samples we had screened cultured ﬁbroblasts for the pro-
duction of and structure of type I procollagen (22) and cells
from all made abnormal proteins. One sample had DNA that
failed to amplify (D5). Of the remaining 63, 27 were from
fetal samples of ,24 weeks gestation. In all instances, the
ultrasound picture or post-termination or post-spontaneous
delivery radiographs were consistent with the diagnosis of
OI type II–minimal calvarial mineralization, very short and
bowed limbs, multiple rib fractures. Among the remaining
36 samples, there was no clinical information for one, one
that left the hospital at 15 days and for whom there was no
follow-up information, and for the remainder there were radio-
graphs or clinical photographs consistent with the diagnosis of
a lethal form of OI, with the usual diagnosis of OI type II.
Patient descriptions are summarized in Supplementary
Material, Table S3. Data on ethnic background were absent
for virtually all samples.
For two of the samples (C3 and D1) there was a record of
familial recurrence of lethal OI. For two others (A3, C2), it
was noted that the father had a milder form of OI, OI type
III or III/IV. No consanguinity was noted in either family.
No prior history of OI was noted in any of the remaining
instances.
Collagen gene sequencing and variant detection
Genomic DNA was isolated from peripheral blood using stan-
dard extraction protocols. For each patient, a total of 14 and
23 kb of genomic DNA for COL1A1 and COL1A2, respect-
ively, were sequenced including all coding regions, intron
sequences for at least 100 bp on either side of each exon
and evolutionarily conserved domains in non-coding regions
(.75% sequence identity between mouse and human).
Primer sequences, PCR conditions and sequence coordinates
of each fragment are published elsewhere (13). All
primers were synthesized by Integrated DNA Technologies
(Coralville, IA, USA).
Sequence traces were aligned with the GenBank reference
sequences of the COL1A1 genomic DNA (AF017178) and
cDNA (NM_000088.3), and the COL1A2 genomic DNA
(AF004877.1) and cDNA (NM_000089.3). Sequence vari-
ations were identiﬁed and conﬁrmed by detection with two
different analysis programs: Sequencher v4.8 (GeneCodes
Human Molecular Genetics, 2009, Vol. 18, No. 3 469Corp., Ann Arbor, MI, USA) and Mutation Surveyor v3.1
(SoftGenetics LLC., State College, PA, USA). Automatic
calls were veriﬁed by inspection. All newly identiﬁed variants
were deposited in dbSNP (14) under the submitter handle
UCSF_HG. All mutations identiﬁed were conﬁrmed by rese-
quencing of genomic DNA taken from reserved samples.
For those samples in which mutations were not detected in
the initial phases of analysis, collagen cDNA was prepared,
ampliﬁed in overlapping fragments of about 1–1.5 kb and
examined by PAGE. For sample C2, the cDNA was ampliﬁed
in two fragments to identify the extent of the genomic del-
etion. If no mutation was identiﬁed in cDNA, genomic DNA
of CRTAP and LEPRE1 was ampliﬁed as described previously
(18) and sequenced.
Collagen mutations are numbered following the
HGVS-approved convention (http://www.hgvs.org/mutno-
men/recs.html), which starts with the translation initiator
methionine as amino acid þ1, and the A of the ATG codon as
nucleotide þ1. Mutations affecting intronic sequence are
referenced to the cDNA sequence. Triple helix positions are
provided for amino acids within the triple helical region of
each proa chain (residues encoded by codons 179–1192 of
the COL1A1 transcript and 91–1104 of COL1A2). The exons
of the COL1A1 gene are numbered consecutively from 1–32.
Exon 33 of the gene is referred to as exon 33–34 by tradition,
to allow the codons of the helical domain to be similar
between the two genes and exons thereafter continue from 35
to 52. Exons of COL1A2 are numbered consecutively.
Each identiﬁed variation was uniquely classiﬁed as either
a SNP, causative mutation, or non-synonymous sequence
variant of unknown signiﬁcance. All substitutions for
glycine within the triple helical domain, mutations that alter
consensus splice sites, insertion or deletion of residues
within the triple helical domain, and mutations that result in
sequence alterations in the carboxyl-terminal propeptides
and that had been previously identiﬁed in individuals with
OI or shown to alter molecular behavior were considered
causative mutations. p.Ala390Thr, p.Glu288Ala, p.Asn855His
and p.Pro146Thr in the proa1(I) chain are categorized as rare
non-synonymous sequence variants of unknown signiﬁcance.
Variations classiﬁed as SNPs are detailed in Supplementary
Material, Tables S1 and S2. SNPs include synonymous vari-
ations and the non-synonymous rs1800215 (p.Ala1075Thr)
in COL1A1 and rs42524 (p.Ala549Pro) in COL1A2. SNPs
are considered novel if they are not listed in build 129 of
dbSNP (14); novel mutations are those not reported in col-
lagen mutation databases (28, Bodian and Klein, manuscript
in preparation).
CRTAP and LEPRE1 mutation detection
Each exon of the CRTAP and LEPRE1 genes was ampliﬁed
and then sequenced as previously described (3,18). All
mutations were conﬁrmed by reampliﬁcation and sequencing
of a new genomic DNA sample.
Lethality prediction
Lethality was predicted using a published method applicable
to single missense mutations altering the Gly-X-Y glycines
in the triple helical region of the proa1(I) chain (12). One
component of the model is a decision tree that classiﬁes
mutations within the N-terminal 178 residues of the triple
helix as non-lethal. Mutations C-terminal to position 178 are
classiﬁed by the amino acid substituting for glycine. Arginine,
valine, aspartic acid and glutamic acid substitutions are pre-
dicted to be lethal, whereas alanine replacements are predicted
to be non-lethal. Cysteine substitutions are tentatively classi-
ﬁed as lethal C-terminal to triple helix position 688. Serine
substitutions for glycine are classiﬁed by a second component
based on an estimate of the thermostability of the Gly-X-Y
triplet C-terminal to the triplet with the substitution. The
models were constructed using the OI triple helical glycine
substitutions mutations published by the OI consortium (5)
as a training set. Predictions for p.Gly884Ser (Gly706Ser)
and p.Gly1094Ser (Gly916Ser) based on preliminary sequen-
cing were published previously (12). For subjects with mul-
tiple variations, the triple helical glycine substitutions are
assumed to be the primary determinant of OI lethality.
Statistical analysis
Conﬁdence intervals were computed using exact distributions
as implemented in R (29).
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